Switching to Maridebart Cafraglutide for Obesity
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
- Age
- 18 – 99
- Sex
- Any
- Trial phase
- Phase 3
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 300 (estimated)
- Sponsor
- Amgen · Industry
This trial is looking for adults who are overweight or obese and have been using a specific medication for weight loss. Participants will switch to taking maridebart cafraglutide and be monitored for effects and side effects.
You may be able to join if
- I have a BMI of 25 or higher.
- I have lost at least 10% of my weight on my current medication.
- My weight has been stable.
- I have been taking the same dose of my current medication.
- I have no gastrointestinal issues.
- I use contraception if I am female.
- I am willing to follow the trial procedures.
You may not be able to join if
- I have obesity due to other medical conditions.
- I have had or plan to have surgery for obesity.
- I have a history of cancer.
- I have diabetes.
- I or my family have a history of medullary thyroid cancer.
- I have participated in a Maridebart Cafraglutide trial before.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your EligibilityEfficacy, safety and tolerability of switching from GLP-1RA to maridebart cafraglutide in adults with obesity or overweight.
Loading trial locations…